Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene

Pharmacotherapy

Volumn 26, Issue 6 I, 2006, Pages 881-885

  Garwood, Candice L ^a   Van Schepen, Kimberly A ^b   McDonough, Randal P ^c   Sullivan, Anne L ^d  

^a WAYNE STATE UNIVERSITY   (United States)

^b CarePro Health Services   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Drug interactions; Hypothyroidism; Levothyroxine; Malabsorption; Raloxifene; Selective estrogen receptor modifiers; SERMs; Thyroid stimulating hormone; Thyroxine; TSH

Indexed keywords

LEVOTHYROXINE; RALOXIFENE; THYROTROPIN;

ADULT; ARTICLE; CASE REPORT; CHRONOPHARMACOLOGY; DRUG ABSORPTION; FEMALE; HUMAN; HYPOTHYROIDISM; OSTEOPOROSIS; THYROTROPIN BLOOD LEVEL; THYROTROPIN RELEASE;

DRUG INTERACTIONS; FEMALE; HUMANS; HYPOTHYROIDISM; MIDDLE AGED; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THYROTROPIN; THYROXINE;

EID: 33744493668     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.6.881     Document Type: Article

References (17)

1. Reasner CA, Talbert RL. Thyroid disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Well BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 5th ed. New York: McGraw-Hill, 2002:1359-78.
2. Sherman SI, Malecha SE. Absorption and malabsorption of levothyroxine sodium. Am J Ther 1995;2:814-18.
3. Siraj ES, Gupta MK, Reddy SS. Raloxifene causing malabsorption of levothyroxine. Arch Intern Med 2003;163:1367-70.
4. Geatti O, Barkan A, Turrin D, Orsolon PG, Shapiro B. L-thyroxine malabsorption due to the injection of herbal remedies. Thyroidology 1993;5:97-102.
5. Csako G, McGriff NJ, Rotman-Pikielny R Sarlis NJ, Pucino F. Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders. Ann Pharmacother 2001;35:1578-83.
6. Anker GB, Lonning PE, Aakvaag A, Lien EA. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scand J Clin Lab Invest 1998;58:103-7.
7. Ceresini G, Morganti S, Rebecchi I, et al. A one-year follow-up on the effects of raloxifene on thyroid function in postmenopausal women. Menopause 2004;11:176-9.
8. Duntas LH, Mantzou E, Koutras DA. Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status. Thyroid 2001;11:779-82.
9. Hsu SH, Cheng WC, Jang MW, Tsai KS. Effects of long-term use of raloxifene, a selective estrogen receptor modulator, on thyroid function test profiles. Clin Chem 2001;47:1865-7.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
11. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002;8:457-69.
12. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
13. Massoudi MS, Meilahn EN, Orchard TJ, et al. Thyroid function and perimenopausal lipid and weight changes: the thyroid study in healthy women. J Womens Health 1997;6:553-8.
14. Bottiglioni F, de Aloysio D, Nicoletti G, Mauloni M, Mantuano R, Capelli M. A study of thyroid function in the pre- and post-menopause. Maturitas 1983;5:105-14.
15. Sowers M, Luborsky J, Perdue C, Araujo KL, Goldman MB, Harlow SD. Thyroid stimulating hormone (TSH) concentrations and menopausal status in women at the mid-life: SWAN. Clin Endocrinol (Oxf) 2003;58:340-7.
16. Erfurth EM, Ericsson UB. The role of estrogen in the TSH and prolactin responses to thyrotropin-releasing hormone in postmenopausal as compared to premenopausal women. Horm Metab Res 1992;24:528-31.
17. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002;8:457-69.